Cadence Pharmaceuticals (NASDAQ: [[ticker:CADX]]), the San Diego-based developer of a new pain medication, said today it has filed an application to seek FDA approval to start selling it in the U.S. The drug, an intravenous form of acetaminophen with the trade name of Acetavance, reached its goal of providing pain relief in a clinical trial. If approved, it would be the first new IV pain reliever approved in the U.S. in more than 20 years, the company said.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
